FDA Clears Updated MRI/Ultrasound Fusion System for Use in Focal Therapy of Prostate Cancer
Advanced annotation with the updated UroNav MRI/ultrasound fusion platform may facilitate enhanced precision and efficiency with focal therapies for prostate cancer.
The Food and Drug Administration (FDA) has granted 510(k) clearance for an updated version of the magnetic resonance imaging (MRI)/ultrasound fusion platform UroNav, which features advanced annotation to improve precision in focal therapy for prostate cancer (PCa).
Combining diagnostic MR images with real-time intra-procedural ultrasound, UroNav facilitates improved targeting of minimally invasive therapeutic procedures for PCa, according to Philips, the manufacturer of UroNav.
The advanced annotation feature with the updated UroNav MRI/ultrasound fusion image navigation platform, recently cleared by the FDA, may enhanced targeted focal therapy for prostate cancer. (Image courtesy of Philips.)
Philips said interventional radiologists and other clinicians may combine UroNav’s advanced annotation feature with its DynaCAD Urology modality to enhance the planning and delivery of focal therapy for patients with PCa.
“We’re entering a new era of precision prostate cancer care. Philips’ integrated focal therapy platform unifies imaging, biopsy pathology, treatment planning and 3D imaging guidance with MR US fusion giving clinicians end‑to‑end efficiency and control,” said Ardeshir Rastinehad, M.D., the vice chair of urology at Lenox Hill Hospital and the system director of prostate cancer at Northwell Health in New York. “With fused imaging and real‑time ablation guidance in one place, we can personalize therapy with greater accuracy and spare patients the unnecessary side effects of traditional treatments.”
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
